Unparalleled in Life Science communication
For more than three decades, Berlin-based BIOCOM has offered professional communication expertise and a wide range of specialist media for the life sciences. For us, scientifc excellence goes hand in hand with sound communication – either as a double qualifcation offered by our individual employees or combined together in project teams. Based on in-depth knowledge of the most recent developments within the life sciences research and business community, we produce high-quality media products and offer targeted services to different clients in the private and public sector.
Since its inception in 2016, the BEAM (Biotech companies in Europe combating AntiMicrobial resistance) Alliance has succeeded in uniting European SMEs involved in the discovery and development of novel antimicrobial therapies and diagnostics. The BEAM Alliance is a unique contributor to help our understanding of the complex array of cross-disciplinary issues mixing science, finance and policymaking. By collaborating with the existing community of global stakeholders, the BEAM Alliance is giving its members a unique voice to recommend bold incentives fitting the needs of SMEs, the driving force of today’s innovation in the field.
European Biotechnology Network
The European Biotechnology Network is dedicated to facilitating co-operation between professionals in biotechnology and the life sciences all over Europe. It has members in all European countries and beyond. As a non-profit organisation the European Biotechnology Network AISBL is registered in Belgium. Since 2007, the constantly growing network has brought research groups, universities, SMEs, large companies and indeed all actors in biotechnology together.
Within IMI’s ND4BB programme, ENABLE (European Gram-negative antibacterial engine) has a €85 million budget to develop compounds active against Gram-negative bacteria. The heart of the project is a drug discovery platform for testing and optimising compounds from hit phase through preclinical phases. ENABLE provides funding for European SMEs and research groups to progress promising programmes up to clinical phase I. ENABLE has the goal to develop at least one phase II-ready compound as well as a pipeline of attractive antimicrobial candidates for FIH clinical trials, bringing new antibiotics to treat Gram-negative infections one step closer to patients.
Sponsors and Exhibitors
A&M Laboratory Group
Situated in the Heart of Europe the A&M Laboratory Group offers GxP compliant analytical services “Made in Germany”. With 250+ dedicated scientists and technicians, state-of-the-art equipment and a 25+ year ﬂawless track record in authority and client audits, A&M is your analytical one-stop shop, supporting the development of your antimicrobial drugs from development to manufacturing. With clients ranging from single person start-ups to big pharma we could be the ideal partner for your outsourcing needs, too.
As a major player in infectious disease diagnostics for over 55 years, bioMérieux has made the fght against antimicrobial resistance one of its core priorities. We offer a unique, comprehensive range of innovative diagnostic solutions that support the responsible use of antibiotics.
- Our high medical value diagnostic solutions identify multi-drug resistant bacteria, reduce antibiotic use by guiding appropriate therapy and track the spread of pathogens.
- We also develop educational resources to raise awareness of AMR and fund global surveys to monitor antibiotic use in hospitals.
BOEHMERT & BOEHMERT
Intellectual property rights are our core competency
As one of the largest and best-known law frms for Intellectual Property (IP) in Europe, we offer our clients any and all services relating to IP. Our company is profcient with assisting clients with patents pertaining to technical inventions and the protection of designs and trademarks. We offer support in copyright, antitrust and competition law in all felds of applied and engineering sciences. We have proven our expertise in traditional as well as young industries, and across borders.
Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X)
CARB-X (Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator) is a global partnership dedicated to accelerating early development antibacterial R&D to address the rising global threat of drug-resistant bacteria. CARB-X is investing $500 million from 2016-2021 to support the development of innovative antibiotics, vaccines, rapid diagnostics and other life-saving products, focusing exclusively on high priority drug-resistant bacteria, especially Gram-negatives. CARB-X is funded by the US Government (BARDA and NIAID), Wellcome Trust, the UK Government (GAMRIF) and the Bill & Melinda Gates Foundation. CARB-X headquarters are at Boston University School of Law.
Collaborative Drug Discovery (CDD)
Collaborative Drug Discovery (CDD) provides an intuitive software suite extensively used by creative biologists and chemists working in academic, biotechnology and pharmaceutical settings. Their ﬂagship product, CDD Vault, enables researchers to intuitively organize and analyse both biological study data and chemical structures, and to collaborate with partners through a straightforward web-interface. CDD helps scientists register chemicals, track inventory, manage bioassay data, capture experiments on its Electronic Laboratory Notebook (ELN), calculate Structure-Activity Relationships (SAR), and mine their data for drug candidates.
German Center for Infection Research (DZIF)
At the German Center for Infection Research (DZIF), about 500 researchers from 35 institutions throughout Germany jointly develop new approaches for the prevention, diagnosis and treatment of infectious diseases. The aim of this nationwide collaboration between universities, hospitals and research institutions is to translate research results into clinical practice quickly and effectively. With this, the DZIF paves the way for developing new vaccines, diagnostic agents and drugs to treat infections. The DZIF is one of six German Centers for Health Research established by the Federal Ministry of Education and Research (BMBF) to combat the most common diseases.
FLANDERS INVESTMENT & TRADE
Flanders Investment and Trade is a government agency dedicated to assisting foreign companies that are considering developing their activity in Flanders - Belgium. Our goal is to facilitate, and the scope of our assistance is very broad, such as: organisation of a series of meetings with regional business leaders & sector inﬂuencers, information on the available workforce, know-how and salaries, information on taxes, work regulations, social contributions in Flanders and Belgium, proposals for offce, warehouse, storage, factory sites based on your specifcations and many more Our services are free of charge for foreign companies looking to set up business and we take care to exercise the level of confdentiality that you request.
Global Antibiotic Research and Development Partnership (GARDP)
The Global Antibiotic Research and Development Partnership (GARDP) is a not-for-proft research and development organization that addresses global public health needs by developing and delivering new or improved antibiotic treatments, while endeavouring to ensure their sustainable access. Initiated by the World Health Organization (WHO) and the Drugs for Neglected Disease initiative (DNDi), GARDP is an important element of WHO’s Global Action Plan on Antimicrobial Resistance that calls for new public-private partnerships to encourage research and development of new antimicrobial agents and diagnostics.
HEMEX, your dynamic consultancy partner and service provider
Our services involve the full range of Regulatory, CMC, QA, Clinical Operations and Medical Affairs expertise, needed to bring your product from the lab to the market. We offer hands-on consultancy and strategic mentoring to the life sciences industry with tailored solutions for start-ups. HEMEX’s experts have several decades of combined experience in the life science industry and a history with the development of anti-infectives and related diagnostic tests. With our headquarters in Liestal, Switzerland and subsidiaries in Loerrach, Germany and Bethesda, USA, we offer worldwide support to our customers.
The InfectoGnostics research campus Jena is a public-private partnership developing new methods in infection diagnostics. In a triad of technology, application and production, more than 30 partners from science, medicine and industry are developing marketable solutions for rapid and cost-effective on-site analysis of infections (point-of-care testing) – such as pneumonia (e.g. caused by antibiotic-resistant pathogens) in human medicine, animal diseases, and pathogen detection in food. The program is supported by its partners and the German ministry BMBF within the Research Campus initiative, an element of the High tech strategy.
LEIBNIZ HEALTH TECHNOLOGIES
A Research Alliance of the Leibniz Association
Providing technological solutions for unmet medical needs − this is the main focus of the 14 members of the interdisciplinary research alliance Leibniz Health Technologies. To battle antimicrobial resistances, the Leibniz Institutes are cooperating in developing e.g. the “RamanBioAssay”, a photonics-based test to determine the effcacy of antibiotics (MIC) in less than 4 hours. The alliance is also inventing therapeutic devices based on cold atmospheric plasma, which is a suitable technology for deactivating various types of microorganisms, including multi-resistant bacteria such as MRSA.
Microsynth (founded in 1989) is a leading European company in the area of nucleic acid synthesis & analysis. The main activities are divided into following three business areas:
- DNA/RNA SYNTHESIS
- DNA/RNA ANALYSYS AND SEQUENCING
- CONTRACT RESEARCH/OUTSOURCING
For almost three decades, the company’s objective has been to serve its customers by delivering products and services of the highest quality, on time and with outstanding service – and all this at competitive prices. Microsynth Seqlab is the German subsidiary of Microsynth AG and is located in Göttingen.
Novo Holdings REPAIR Impact Fund
Novo Holdings established the REPAIR Impact Fund commissioned by the Novo Nordisk Foundation in February 2018 with a total budget of USD 165 million to invest in companies involved in discovering and the early-stage development of therapies targeting resistant microorganisms. Novo Holdings manages ~EUR 50bn of assets on behalf of the Novo Nordisk Foundation. Novo Holdings invests exclusively in life science and actively supports more than 100 life science companies – from start-ups to well-established multinational companies.
Polyphor is a clinical stage, Swiss biopharmaceutical company which has discovered and is developing a novel class of Gram negative Antibiotics Targeting the Outer Membrane Proteins (OMPTA). The company’s lead product, murepavadin, is in Phase III development against Pseudomonas aeruginosa – recognized as a critical priority 1 pathogen by WHO. Murepavadin is also being developed as an inhaled version for Cystic Fibrosis and other lung diseases. Broad spectrum OMPTAs are in advanced preclinical stage with frst compound planned to enter clinical development during 2020 (co-funded by Novo Repair Fund and Carb-X). Polyphor is listed on the SIX Swiss Exchange (SIX: POLN).
Resistell proposes an alternative to culture based antibiogram, the current gold standard in antibiotic susceptibility testing. Our offering is a diagnostic device. The method is based on ground breaking invention from EPFL Lausanne - the detection of movement caused by living bacterial cells. Because the test is growth independent, we reduce the time taken to get a result from days to minutes. Our mission is to provide the physicians with the diagnostic tool that will enable them to choose the most effcient but also most narrow spectrum antibiotic for the patient. We want to contribute to better treatment but also prevent spreading of AMR.
sphingotec GmbH in Hennigsdorf, Germany, develops and markets the innovative biomarkers penKid® and bio-ADM® for the diagnosis, monitoring and therapy control of heart failure, acute kidney injury and septic shock, as well as and the Nexus IB10 POC platform, which was acquired in May 2018 with the acquisition of the Samsung subsidiary Nexus Dx Inc. The product portfolio of the company, which was founded in 2002 by Dr. Andreas Bergmann, also includes biomarkers that help identify and prevent health risks before they manifest themselves, including obesity, cardiovascular diseases and breast cancer.
The UK’s Department for International Trade
The UK’s Department for International Trade (DIT) is a specialist Government department that helps businesses export, drives inward and outward investment, negotiates market access and trade deals, and champions free trade. DIT
- helps UK-based companies access overseas markets, providing confdential advice and support necessary to assist you in achieving your export goals.
- helps overseas companies bring their high-level investment to the UK, providing professional, personalised and practical assistance and advice.
These services are offered through DIT’s extensive network of sector & market specialists in offces all over the world.
BioPartner UK is the accredited trade organisation that provides practical support and international promotion to UK Life Sciences companies, who wish to grow their business overseas. BioPartner signposts to UK expertise and leads delegations to promote the UK presence at major international biopharma conferences. By operating in partnership with the UK government and event organisers, BioPartner assists all UK companies with access to government grants and heavily discounted entry fees. Members of the BioPartner Programme receive extra benefts and support to effectively trade overseas.
European Biotechnology Life Sciences & Industry Magazine
For almost two decades, the European Biotechnology Life Sciences & Industry Magazine has been covering the scientifc, political and economic development of biotechnology and life sciences in the 28 countries of the European Union as well as in Switzerland and Norway. With a circulation of more than 13,000 copies, the European Biotechnology Magazine is the leading European specialist journal for life sciences. Daily news is available online at